Results 181 to 190 of about 21,799 (237)

Clinical and Real-World Evidence on Etanercept Biosimilar Switching: A Narrative Literature Review of Efficacy and Safety. [PDF]

Adv Ther
Schmalzing M, Askari A, Girolomoni G, Perez-Coleman JCV, Salvati C, Bachinskaya E.   +5 more
europepmc   +1 more source

Regulatory Requirements for Interchangeable Biosimilar Designation. [PDF]

Ther Innov Regul Sci
Samy PJ, Mouslim MC, Bennett CL, Trujillo AJ.   +3 more
europepmc   +1 more source

Cost-utility and budget impact analysis of biosimilar trastuzumab for early-stage HER2-positive breast cancer in Thailand: an updated evaluation supporting expanded access. [PDF]

BMC Health Serv Res
Lochid-Amnuay S, Kongsakon R.
europepmc   +1 more source

Efficacy and Safety of Switching from Adalimumab Originator to SB5 Biosimilar in Noninfectious Uveitis: Early Clinical Outcomes. [PDF]

J Clin Med
Song JH, Kim C, Chung YR, Kim HR.
europepmc   +1 more source

An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany. [PDF]

Front Public Health
Raitner I, Müller B, Vijayan A, Zimmermann L, Bramlage P, Ness NH, Müller M.   +6 more
europepmc   +1 more source

Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study. [PDF]

BioDrugs
Car E, Barbier L, Schwarzenberger I, Huys I, Simoens S, Vulto AG.   +5 more
europepmc   +1 more source

Efficacy and safety of sintilimab plus a bevacizumab biosimilar combined with transarterial chemoembolization for advanced hepatocellular carcinoma. [PDF]

Medicine (Baltimore)
Yang J, Xu Q, Wu S.
europepmc   +1 more source

A comparative analysis of biologics market dynamics in 12 countries: (Bio)similar and sustainability. [PDF]

Front Pharmacol
Song Y, Shin G, Choi G, Han E, Ou HT, Bae S.   +5 more
europepmc   +1 more source